SCHEMBL793558

SCHEMBL793558

CCOC(=O)c1sc(NS(=O)(=O)c2cc(-c3cc(F)ccc3F)c(Cl)s2)nc1C

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.62
LMNA P02545 2/20 0.62
HTT P42858 3/20 0.55
KMT2A Q03164 7/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
MEN1 O00255 5/20 0.54
CYP2C9 P11712 1/20 0.54
KDM4E B2RXH2 4/20 0.51
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
HPGD P15428 3/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
MAPT P10636 4/20 0.48
DHODH Q02127 3/20 0.48
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL793764 0.88 ALDH1A1 (0.45) ALDH1A1LMNAHTTKMT2ASMN1; SMN2
SCHEMBL30268487 0.83 HSD11B1 (0.42) ALDH1A1LMNAHTT
SCHEMBL793187 0.79 PFKFB3 (0.39) ALDH1A1LMNAHTTNPC1RAB9A
SCHEMBL30268167 0.76 PYGL (0.41) ALDH1A1LMNAHTTKMT2ASMN1; SMN2
SCHEMBL30268509 0.75 SCN9A (0.40) KMT2ASMN1; SMN2MEN1RAB9ANFKB1
SCHEMBL5911721 0.74 HTT (0.68) ALDH1A1LMNAHTTKMT2ASMN1; SMN2
SCHEMBL5911658 0.72 HTT (0.64) ALDH1A1LMNAHTTKMT2ASMN1; SMN2
SCHEMBL15055047 0.72 PFKFB3 (0.51) ALDH1A1LMNAKMT2ASMN1; SMN2MEN1
SCHEMBL1540240 0.71 ALDH1A1 (0.67) ALDH1A1LMNAHTTKMT2ASMN1; SMN2
SCHEMBL15055847 0.70 PFKFB3 (0.51) ALDH1A1SMN1; SMN2HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US claimed
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 EP claimed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US claimed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 EP disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 ALDH1A1 1943/4885LMNA 4383/4885HTT 1690/4885
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA ALDH1A1 390/4885LMNA 1654/4885HTT 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.